Bayes Pharma Innovator Pharmacogenomics / Precision Dosing
Checking PGx service Back to Innovator
Precision Medicine / Pharmacogenomics

Genotype-aware dosing strategy
for clinical development planning.

CPIC-guideline dosing logic across 13 gene-drug pairs -- tacrolimus, carbamazepine, phenytoin, warfarin, clopidogrel, voriconazole, codeine, atomoxetine, abacavir, allopurinol, thiopurines, fluoropyrimidines, and simvastatin -- with a population-frequency prior for dose-strategy and enrollment planning when a cohort's genotype distribution isn't known yet, corroborated live against India's GenomeIndia database (GI-DB, 9,768 individuals, IGIB) and PharmGKB clinical annotation evidence. Also feeds cohort stratification in Trial Simulator.

Open Trial Simulator
Decision-support only. Population-prior estimates apply only when a genotype/test result is unknown and are not a diagnosis. Intended for dose-strategy and protocol planning during development, not individual patient prescribing. Verify against current CPIC/PharmGKB guidance and use qualified clinical pharmacology / clinical pharmacist review before any protocol or prescribing decision.

Tacrolimus starting dose -- CYP3A5

CPIC: expressers need ~1.5-2x the non-expresser starting dose.

Carbamazepine safety screen -- HLA-B*15:02

CPIC/FDA: test before starting in patients of Asian (incl. Indian) ancestry.

Phenytoin dose adjustment -- CYP2C9

CPIC: PM ≥50% reduction, IM ≥25% reduction of starting dose.

10 additional CPIC gene-drug pairs

Warfarin, clopidogrel, voriconazole, codeine, atomoxetine, abacavir, allopurinol, thiopurines, fluoropyrimidines, simvastatin.

PharmGKB clinical evidence lookup

Clinical annotation counts and evidence levels for any pharmacogene, sourced live from PharmGKB.